{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:34:10Z","timestamp":1790249650382,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.japh.2021.01.025","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T10:29:41Z","timestamp":1614680981000},"page":"e218-e224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Gabapentin controlled substance status"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8593-9735","authenticated-orcid":false,"given":"Levi S.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany N.","family":"Coomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranee J.","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2021.01.025_bib1","series-title":"Neurontin [Package Insert]","year":"2017"},{"issue":"4","key":"10.1016\/j.japh.2021.01.025_bib2","first-page":"266","article-title":"Gabapentin use in a managed Medicaid population","volume":"8","author":"Hamer","year":"2002","journal-title":"J\u00a0Manag Care Pharm"},{"issue":"9853","key":"10.1016\/j.japh.2021.01.025_bib4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0140-6736(12)60776-4","article-title":"Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Ryan","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.japh.2021.01.025_bib5","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/art.22457","article-title":"Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"56","author":"Arnold","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.japh.2021.01.025_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.amjmed.2004.03.019","article-title":"Gabapentin for intractable hiccup","volume":"117","author":"Hern\u00e1ndez","year":"2004","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.japh.2021.01.025_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2340\/00015555-1400","article-title":"European guideline on chronic pruritus","volume":"92","author":"Weisshaar","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.japh.2021.01.025_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.AOG.0000222383.43913.ed","article-title":"Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial","volume":"108","author":"Reddy","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.japh.2021.01.025_bib9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians","volume":"166","author":"Radley","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.japh.2021.01.025_bib10","author":"Slaton"},{"issue":"6","key":"10.1016\/j.japh.2021.01.025_bib12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40263-014-0164-4","article-title":"Misuse and abuse of pregabalin and gabapentin: cause for concern?","volume":"28","author":"Schifano","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.japh.2021.01.025_bib14","series-title":"Lyrica [package insert]","year":"2011"},{"issue":"5","key":"10.1016\/j.japh.2021.01.025_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004714-199710000-00012","article-title":"Gabapentin abuse in a cocaine user: implications for treatment?","volume":"17","author":"Markowitz","year":"1997","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.japh.2021.01.025_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/10550490490460300","article-title":"Gabapentin abuse in inmates with prior history of cocaine dependence","volume":"13","author":"Reccoppa","year":"2004","journal-title":"Am J Addict"},{"issue":"3","key":"10.1016\/j.japh.2021.01.025_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4088\/JCP.v68n0320a","article-title":"Gabapentin abuse, and delirium tremens upon gabapentin withdrawal","volume":"68","author":"Pittenger","year":"2007","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.japh.2021.01.025_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000355268","article-title":"Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers","volume":"20","author":"Baird","year":"2014","journal-title":"Eur Addict Res"},{"issue":"6","key":"10.1016\/j.japh.2021.01.025_bib19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ajp.2014.13111526","article-title":"Potentiation of the effect of buprenorphine\/naloxone with gabapentin or quetiapine","volume":"171","author":"Reeves","year":"2014","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.japh.2021.01.025_bib20","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1176\/appi.neuropsych.13110339","article-title":"Gabapentin dependence in a patient with opioid dependence syndrome","volume":"27","author":"Satish","year":"2015","journal-title":"J\u00a0Neuropsychiatr Clin Neurosci"},{"issue":"6","key":"10.1016\/j.japh.2021.01.025_bib21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.japh.2021.01.025_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1213\/00000539-200007000-00035","article-title":"Gabapentin enhances the analgesic effect of morphine in healthy volunteers","volume":"91","author":"Eckhardt","year":"2000","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.japh.2021.01.025_bib23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.japh.2021.01.025_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1176\/appi.ajp.2014.14101272","article-title":"Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky","volume":"172","author":"Smith","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.japh.2021.01.025_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2018.01.018","article-title":"Prevalence of gabapentin in drug overdose postmortem toxicology testing results","volume":"186","author":"Slavova","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.japh.2021.01.025_bib26","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/1556-4029.14021","article-title":"Gabapentin-related deaths: patterns of abuse and postmortem levels","volume":"64","author":"Tharp","year":"2019","journal-title":"J\u00a0Forensic Sci"},{"issue":"7931","key":"10.1016\/j.japh.2021.01.025_bib28","article-title":"Open to abuse: gaps highlighted in the controlled drug system","volume":"303","author":"Robinson","year":"2019","journal-title":"Pharm J"},{"issue":"4","key":"10.1016\/j.japh.2021.01.025_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00007691-200308000-00007","article-title":"Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study","volume":"25","author":"Lindberger","year":"2003","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.japh.2021.01.025_bib31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40268-016-0148-6","article-title":"An updated overview on therapeutic drug monitoring of recent antiepileptic drugs","volume":"16","author":"Jacob","year":"2016","journal-title":"Drugs R D"},{"issue":"6","key":"10.1016\/j.japh.2021.01.025_bib32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/00007691-200412000-00008","article-title":"Association between patient age and gabapentin serum concentration-to-dose ratio: a preliminary multivariate analysis","volume":"26","author":"Armijo","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.japh.2021.01.025_bib33","first-page":"22","article-title":"Dose dependent urine concentrations of gabapentin (Neurontin)","volume":"5","author":"Feng","year":"2020","journal-title":"J\u00a0Pharmaceut Res"},{"issue":"5","key":"10.1016\/j.japh.2021.01.025_bib34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004714-199710000-00012","article-title":"Gabapentin abuse in a cocaine user: implications for treatment?","volume":"17","author":"Markowitz","year":"1997","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.japh.2021.01.025_bib35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/10550490490460300","article-title":"Gabapentin abuse in inmates with prior history of cocaine dependence","volume":"13","author":"Reccoppa","year":"2004","journal-title":"Am J Addict"},{"issue":"3","key":"10.1016\/j.japh.2021.01.025_bib36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4088\/JCP.v68n0320a","article-title":"Gabapentin abuse, and delirium tremens upon gabapentin withdrawal","volume":"68","author":"Pittenger","year":"2007","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.japh.2021.01.025_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000355268","article-title":"Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers","volume":"20","author":"Baird","year":"2014","journal-title":"Eur Addict Res"},{"issue":"6","key":"10.1016\/j.japh.2021.01.025_bib38","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ajp.2014.13111526","article-title":"Potentiation of the effect of buprenorphine\/naloxone with gabapentin or quetiapine","volume":"171","author":"Reeves","year":"2014","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.japh.2021.01.025_bib39","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1176\/appi.neuropsych.13110339","article-title":"Gabapentin dependence in a patient with opioid dependence syndrome","volume":"27","author":"Satish","year":"2015","journal-title":"J\u00a0Neuropsychiatr Clin Neurosci"},{"key":"10.1016\/j.japh.2021.01.025_bib43","author":"Hardy"},{"key":"10.1016\/j.japh.2021.01.025_bib44","author":"Hawk"},{"key":"10.1016\/j.japh.2021.01.025_bib46","author":"Selby"},{"key":"10.1016\/j.japh.2021.01.025_bib50","author":"Blasi"},{"key":"10.1016\/j.japh.2021.01.025_bib51","author":"Lavery"},{"key":"10.1016\/j.japh.2021.01.025_bib52","author":"Wiberg"},{"key":"10.1016\/j.japh.2021.01.025_bib53","doi-asserted-by":"crossref","unstructured":"Balick R. Nebraska pharmacists will report all prescriptions to state PDMP. Pharmacy Today. Available at: https:\/\/www.pharmacytoday.org\/article\/S1042-0991(17)31645-6\/pdf;23(11):50\u201351. Accessed November 10,\u00a02020.","DOI":"10.1016\/j.ptdy.2017.10.009"},{"key":"10.1016\/j.japh.2021.01.025_bib55","author":"Schierholt"},{"key":"10.1016\/j.japh.2021.01.025_bib56","author":"Schnabel"},{"key":"10.1016\/j.japh.2021.01.025_bib57","author":"Catizone"},{"key":"10.1016\/j.japh.2021.01.025_bib58","author":"Shaw"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319121000273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319121000273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:48:23Z","timestamp":1761544103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319121000273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1544319121000273"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2021.01.025","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gabapentin controlled substance status","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2021.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}